Publications
Detailed Information
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pivot, Xavier | - |
dc.contributor.author | Im, Seock Ah | - |
dc.contributor.author | Guo, Matthew | - |
dc.contributor.author | Marme, Frederik | - |
dc.date.accessioned | 2022-03-22T09:24:11Z | - |
dc.date.available | 2022-03-22T09:24:11Z | - |
dc.date.created | 2019-06-04 | - |
dc.date.created | 2019-06-04 | - |
dc.date.created | 2019-06-04 | - |
dc.date.created | 2019-06-04 | - |
dc.date.issued | 2018-05 | - |
dc.identifier.citation | Breast Cancer, Vol.25 No.3, pp.370-374 | - |
dc.identifier.issn | 1340-6868 | - |
dc.identifier.other | 74706 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177317 | - |
dc.description.abstract | This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and <= 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m(2) intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m(2) on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles. | - |
dc.language | 영어 | - |
dc.publisher | Maruzen Co., Ltd/Maruzen Kabushikikaisha/Springer Japan | - |
dc.title | Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s12282-017-0826-4 | - |
dc.citation.journaltitle | Breast Cancer | - |
dc.identifier.wosid | 000430419700016 | - |
dc.identifier.scopusid | 2-s2.0-85040047029 | - |
dc.citation.endpage | 374 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 370 | - |
dc.citation.volume | 25 | - |
dc.identifier.sci | 000430419700016 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PRETREATED PATIENTS | - |
dc.subject.keywordPlus | ANTHRACYCLINE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | MESYLATE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordAuthor | Subgroup analysis | - |
dc.subject.keywordAuthor | Eribulin | - |
dc.subject.keywordAuthor | Capecitabine | - |
dc.subject.keywordAuthor | Metastatic breast cancer | - |
dc.subject.keywordAuthor | Overall survival | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.